Accugenix

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Euro

HSTS

DNSSEC

Google Maps

WordPress

Font Awesome

Mobile Non Scaleable Content

Corporate Vice President Finance, CFO Safety Assessment Division

Andrea Romoli

Chief Technology Officer (Early Discovery)

David Fischer

Corporate Executive Vice President & General Counsel

David Johst

Corporate Vice President and General Manager, Microbial Solutions Division of Charles River Labs

Greg Marshall

Chairman, President & Chief Executive Officer

James Foster

Senior Director

Jeff Haskins

Senior Vice President, Chief Scientific Officer

Julie Frearson

Business Management

Michael Hawk

Principal Scientist II, in Vitro Metabolism at Charles River Laboratories

Patty Walton

Chief Technology Officer

Stephen Speirs

Craig Thompson

Robert Bertolini

Jacob McDaniel

Director of Experience Design

William D. Barbo

Executive Vice President & Chief Commercial Officer

Chris Lowrie

Senior Director, Lab Sciences

Anja Tessarz

Scientific Specialist Viral Clearance

Virginia M. Wilson

Director

Gina Mullane

Sr. Vice President Client Experience and Chief Marketing Officer

Greg Mason

Sr. Director, Global Category Procurement, Lab Operations

Tiffany Granacki

Director, Sales and Marketing

Aspect Medical Systems is engaged in developing brain monitoring technology solutions.

Biotechnology Companies With More Than 100 Employees

Greater Boston Area Companies With More Than $10M in Revenue

East Coast Companies With More Than 50 Employees (Top 10K)

Investors Active in East Coast (Top 10K)

Charles River Laboratories International, Inc. provides solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. Segments The company has two segments: Research Models and Services (RMS) and Preclinical Services (PCS), which includes Phase I clinical services. RESEARCH MODELS AND SERVICES (RMS) The company supplies research models to the drug development industry. With approximately 150 different strains the company engages in the production and sale of research models, principally genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist customers in supporting the use of research models in drug development. With multiple facilities located on three continents (North America, Europe and Asia (Japan)), the company maintains production centers, including a total of approximately 180 barrier rooms or isolator facilities located near its customers. RMS segment comprises Research Models, Research Model Services, and other related products and services

The Foundation for Chemistry Research and Initiatives

Grant - Charles River Laboratories International

Post-IPO Debt - Charles River Laboratories International

Post-IPO Equity - Charles River Laboratories International

Computer and Software Services and Scientific Services

Wilmington

Massachusetts

United States

North America

Charles River Laboratories International

$6.1 Bn Dietary Supplement Testing Services Global Market Opportunities and Strategies to 2033: Contaminant Testing Platforms, Adulteration Panel Analysis, AI-Driven Platforms for Improved Testing

Charles River Labs closes several locations, 1,300+ jobs cut in cost saving initiative

Eminence Capital buys Gitlab, Charles River, exits Haleon, others in Q3

$56.72 Bn Drug Discovery Services Market Opportunities and Strategies to 2033: Comprehensive Solutions for Enhanced Biotech Industry Support, Strategic Collaborations Among Major Players

Analyst recommendations: Corteva, Dollar Tree, JPMorgan, Microsoft, Palantir...

Charles River Q3 Earnings: CEO Notes Improved Biotech Funding And Stabilizing Demand - Here's Why

Charles River Laboratories Announces Third-Quarter 2024 Results

global preclinical medical device testing services market

Those who invested in Charles River Laboratories International (NYSE:CRL) five years ago are up 50%

Spain

Europe

Germany

Italy

United Kingdom

HTML5

DigiCert

Wistia

Microsoft Outlook

Google Maps API

Fonts.com

F5 NGINX

Adobe Flash

Twilio

Google Tag Manager

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

news impact assignment basic	general	Mar 8, 2024 1:20 PM	c7f2856c
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	4439f7b1
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:20 PM	421280f0
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	90ef51fa
crunchbase profile	general	Nov 25, 2024 9:41 AM	831b9a32
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:52 PM	7478288f
peers	general
news basic	general	Dec 4, 2024 2:13 PM	50cbd4b7
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CRIVER

Charles River Laboratories International, Inc.

Last Close

194.19

22/11 21:00

Market Cap

10.44B

Beta: -

Volume Today

575.72K

Avg: -